Neurocrine Biosciences (NBIX) Competitors $136.63 -1.84 (-1.33%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$136.60 -0.03 (-0.02%) As of 10/10/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NBIX vs. BIIB, UTHR, INCY, EXEL, BMRN, IONS, EXAS, MDGL, HALO, and RGENShould you be buying Neurocrine Biosciences stock or one of its competitors? The main competitors of Neurocrine Biosciences include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Ionis Pharmaceuticals (IONS), Exact Sciences (EXAS), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry. Neurocrine Biosciences vs. Its Competitors Biogen United Therapeutics Incyte Exelixis BioMarin Pharmaceutical Ionis Pharmaceuticals Exact Sciences Madrigal Pharmaceuticals Halozyme Therapeutics Repligen Biogen (NASDAQ:BIIB) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations. Which has more volatility & risk, BIIB or NBIX? Biogen has a beta of 0.13, indicating that its stock price is 87% less volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Does the media prefer BIIB or NBIX? In the previous week, Biogen had 26 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 40 mentions for Biogen and 14 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 0.82 beat Biogen's score of 0.65 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 13 Very Positive mention(s) 2 Positive mention(s) 11 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in BIIB or NBIX? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 4.8% of Neurocrine Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Do analysts prefer BIIB or NBIX? Biogen presently has a consensus target price of $180.15, suggesting a potential upside of 22.91%. Neurocrine Biosciences has a consensus target price of $163.44, suggesting a potential upside of 19.63%. Given Biogen's higher possible upside, equities research analysts plainly believe Biogen is more favorable than Neurocrine Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 1 Sell rating(s) 19 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.32Neurocrine Biosciences 0 Sell rating(s) 4 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 2.80 Is BIIB or NBIX more profitable? Biogen has a net margin of 15.31% compared to Neurocrine Biosciences' net margin of 13.88%. Biogen's return on equity of 13.85% beat Neurocrine Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.31% 13.85% 8.32% Neurocrine Biosciences 13.88%13.22%9.39% Which has better valuation and earnings, BIIB or NBIX? Biogen has higher revenue and earnings than Neurocrine Biosciences. Biogen is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.22$1.63B$10.4614.01Neurocrine Biosciences$2.36B5.75$341.30M$3.3840.42 SummaryNeurocrine Biosciences beats Biogen on 9 of the 16 factors compared between the two stocks. Get Neurocrine Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NBIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NBIX vs. The Competition Export to ExcelMetricNeurocrine BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$13.73B$2.70B$6.11B$10.63BDividend YieldN/A56.72%5.67%4.71%P/E Ratio40.4223.2285.9726.57Price / Sales5.75740.03611.53132.55Price / Cash40.97179.8938.5062.09Price / Book5.345.3712.756.53Net Income$341.30M$32.78M$3.31B$276.43M7 Day Performance-0.29%2.01%0.80%-0.88%1 Month Performance-4.85%7.66%6.21%3.55%1 Year Performance18.30%-1.74%80.34%37.91% Neurocrine Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NBIXNeurocrine Biosciences4.7719 of 5 stars$136.63-1.3%$163.44+19.6%+21.5%$13.73B$2.36B40.421,800Analyst ForecastBIIBBiogen4.6143 of 5 stars$138.52+0.8%$182.04+31.4%-22.3%$20.31B$9.68B13.247,605Trending NewsAnalyst ForecastAnalyst RevisionUTHRUnited Therapeutics4.312 of 5 stars$424.31-1.9%$449.57+6.0%+24.2%$19.14B$2.88B16.561,305Positive NewsAnalyst ForecastInsider TradeINCYIncyte4.3767 of 5 stars$83.89+1.4%$83.67-0.3%+28.2%$16.38B$4.24B19.072,617Analyst ForecastEXELExelixis4.8309 of 5 stars$40.57+3.9%$44.42+9.5%+48.4%$10.92B$2.17B19.501,147Trending NewsAnalyst ForecastAnalyst RevisionBMRNBioMarin Pharmaceutical4.9281 of 5 stars$54.02+0.3%$92.60+71.4%-25.1%$10.37B$2.85B16.033,040Trending NewsAnalyst ForecastAnalyst RevisionIONSIonis Pharmaceuticals3.4767 of 5 stars$64.15+0.1%$73.88+15.2%+84.4%$10.22B$705M-34.861,069Trending NewsAnalyst ForecastInsider TradeEXASExact Sciences4.4157 of 5 stars$53.38-0.4%$68.05+27.5%-15.9%$10.11B$2.76B-9.837,000Trending NewsAnalyst ForecastInsider TradeMDGLMadrigal Pharmaceuticals4.3628 of 5 stars$443.10+4.4%$495.88+11.9%+104.0%$9.84B$180.13M-34.4890News CoverageAnalyst ForecastHALOHalozyme Therapeutics4.7454 of 5 stars$73.29-0.6%$69.89-4.6%+23.0%$8.57B$1.02B16.77390Trending NewsAnalyst UpgradeAnalyst RevisionRGENRepligen4.6597 of 5 stars$124.09-1.2%$168.75+36.0%+8.0%$6.98B$634.44M-496.341,778Analyst Forecast Related Companies and Tools Related Companies Biogen Competitors United Therapeutics Competitors Incyte Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Ionis Pharmaceuticals Competitors Exact Sciences Competitors Madrigal Pharmaceuticals Competitors Halozyme Therapeutics Competitors Repligen Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NBIX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurocrine Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
